Ziprasidone, Serum or Plasma
2007955
Ordering Recommendation
Therapeutic monitoring of ziprasidone (eg, Zeldox, Geodon).
Mnemonic
ZIPRASIDO
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun, Wed
Reported
1-5 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Pre-dose (trough) draw - At steady state concentration.  
Collect
Lavender (EDTA), pink (K2EDTA) or plain red.  
Specimen Preparation
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL)  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).  
Remarks
  
Stability
Ambient: 2 weeks Refrigerated: 2 weeks; Frozen: 2 weeks  
Reference Interval
 
 
Therapeutic range Not well established
Proposed Dose-​Related Range 50-​200 ng/mL
Toxic range Not well established
Interpretive Data
Adverse effects to ziprasidone therapy may include headache, postural hypotension, tachycardia and dyskinesia.

See Compliance Statement B: www.aruplab.com/CS
Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
 
Note
 
CPT Code(s)
80299
Components
Component Test Code*Component Chart NameLOINC
2007956Ziprasidone Serum/Plasma33946-5
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • geodon blood concentration
  • zeldex blood concentration
  • Zeldox, Geodon
  • ziprasidone blood level